The CYTR chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYTR chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CYTR stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CYTR Detailed Price Forecast - CNN Money||View CYTR Detailed Summary - Google Finance|
|View CYTR Detailed Summary - Yahoo! Finance||View CYTR Stock Research & Analysis - Zacks.com|
|View CYTR Trends & Analysis - Trade-Ideas||View CYTR Major Holders - Barrons|
|View CYTR Call Transcripts - NASDAQ||View CYTR Breaking News & Analysis - Seeking Alpha|
|View CYTR Annual Report - CompanySpotlight.com||View CYTR OTC Short Report - OTCShortReport.com|
|View CYTR Fundamentals - TradeKing||View CYTR SEC Filings - Bar Chart|
|View Historical Prices for CYTR - The WSJ||View Performance/Total Return for CYTR - Morningstar|
|View the Analyst Estimates for CYTR - MarketWatch||View the Earnings History for CYTR - CNBC|
|View the CYTR Earnings - StockMarketWatch||View CYTR Buy or Sell Recommendations - MacroAxis|
|View the CYTR Bullish Patterns - American Bulls||View CYTR Short Pain Metrics - ShortPainBot.com|
|View CYTR Stock Mentions - StockTwits||View CYTR Stock Mentions - PennyStockTweets|
|View CYTR Stock Mentions - Twitter||View CYTR Investment Forum News - Investor Hub|
|View CYTR Stock Mentions - Yahoo! Message Board||View CYTR Stock Mentions - Seeking Alpha|
|View Insider Transactions for CYTR - SECform4.com||View Insider Transactions for CYTR - Insider Cow|
|View CYTR Major Holdings Summary - CNBC||View Insider Disclosure for CYTR - OTC Markets|
|View Insider Transactions for CYTR - Yahoo! Finance||View Institutional Holdings for CYTR - NASDAQ|
|View CYTR Stock Insight & Charts - FinViz.com||View CYTR Investment Charts - StockCharts.com|
|View CYTR Stock Overview & Charts - BarChart||View CYTR User Generated Charts - Trading View|
LOS ANGELES, June 7, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted clinical data from partner NantCell's poster presentation on June 2, 2018 at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, in Chicago. The data clearly demonstrates the lack of cardiac toxicity associated with treatment with aldoxorubicin.
LOS ANGELES, June 4, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the formation and launch of Centurion BioPharma Corporation, a private wholly owned subsidiary that will focus on advancing the Company's proprietary, albumin binding ultra-high potency LADR™ (Linker-Activated Drug Release) oncology drug candidates. CytRx has transferred to Centurion BioPharma all of the assets, liabilities and personnel associated with its laboratory operations in Freiburg, Germany. Administrative Offices are located in Los Angeles, California.
CytRx Corporation to Present at 8th Annual LD Micro Invitational Conference
Posted on Wednesday May 30, 2018
LOS ANGELES, May 30, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. John Caloz, Chief Financial Officer, will present at the 8th Annual LD Micro Invitational Conference on Tuesday, June 5, 2018 at 1:30 P.M. Pacific Daylight Time at the Luxe Sunset Boulevard Hotel in Bel-Air. Mr. Caloz will discuss the LADR™ platform, its broad potential in treating various tumor types, its advantages over antibody drug conjugates and an example of a LADR™ surrogate product proof of concept (aldoxorubicin). He will also address the goal of obtaining pharmaceutical partnerships to develop the LADR™ pipeline candidates that are eligible for Investigational New Drug (IND)-enabling studies. In excess of 1,000 people are expected to attend the Invitational, to hear presentations from more than 200 leading microcap companies.
LOS ANGELES, May 17, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that clinical data showing the lack of cardiac toxicity associated with treatment with partner NantCell's aldoxorubicin will be featured in a poster presentation at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, taking place June 1-5, 2018 in Chicago. The data were obtained from two clinical trials of aldoxorubicin, a rationally-engineered cytotoxic which employs a linker bound to albumin to deliver doxorubicin directly into the tumor.